Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

By LabMedica International staff writers
Posted on 15 Jun 2026

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. More...

In England, reports of acquired carbapenemase producers more than doubled between 2021 and 2023, and undetected carriage can trigger outbreaks, longer stays, and higher mortality. A newly launched 30-month real-world study now evaluates whether rapid molecular CPE screening can accelerate infection control decisions and inform National Health Service (NHS) policy.

The TRACE-CPE study is being delivered by the Fleming Initiative, a partnership between Imperial College London and Imperial College Healthcare NHS Trust, in collaboration with Cepheid. Conducted over two and a half years at Imperial College Healthcare NHS Trust and Guy’s and St Thomas’ NHS Foundation Trust, the program will generate evidence to guide the use of rapid antimicrobial resistance (AMR) screening in large, complex acute-care settings. The findings are intended to support hospital operations and inform national screening policy.

The technology under evaluation is rapid molecular CPE screening, which can return results in approximately one hour, compared with around 48 hours for culture-based methods. Investigators will test these diagnostics in frontline NHS workflows to measure effects on clinical practice, infection prevention and control, and hospital transmission. The protocol also includes analysis of patient risk factors and colonization patterns to clarify how CPE spreads within hospitals.

Beyond turnaround time, TRACE-CPE will examine how rapid screening integrates into routine processes and impacts health-system productivity, patient experience, and costs. The study aims to strengthen antimicrobial stewardship (AMS), support delivery of the National Action Plan (NAP), and align with the NHS 10-year plan. By drawing on patient populations representative of high-volume acute care, the project seeks to produce a robust evidence base for decision-makers.

Ultimately, the research is designed to provide policymakers, hospital leaders, and clinicians with practical data on when and how rapid molecular CPE screening should be implemented across the NHS and in comparable health systems facing rising drug resistance.

“Antimicrobial resistance will not be addressed effectively by awareness alone. It will be solved by evidence, translated into practice, in the places where antibiotic decisions are actually made,” said Dr. Jonathan Otter, Director of Infection Prevention and Control at Guy’s and St Thomas’ NHS Foundation Trust and Principal Investigator for TRACE-CPE. “TRACE-CPE is the sort of cross-disciplinary collaboration the Fleming Initiative was created to enable. Our aim is a future where CPE does not spread in our hospitals, and rapid, accurate testing is central to making that future real.”

Related Links
Fleming Initiative


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Neurofilament Light Chain Assay
Lumipulse G NfL Blood
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.